Phase 3 Clinical Trials With Primary Completion Dates in June 2017

This is a list of Phase 3 trials with primary completion dates in June 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
AERI Aerie Pharmaceuticals, Inc. 2017-06-01 Phase 3 NCT02558400 Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
AMAG AMAG Pharmaceuticals, Inc. 2017-06-01 Phase 3 NCT02694978 A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
ARDX Ardelyx, Inc. 2017-06-01 Phase 3 NCT02621892 A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
AXSM Axsome Therapeutics, Inc. 2017-06-01 Phase 3 NCT02504008 CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1
BIVV Bioverativ Inc. 2017-06-01 Phase 3 NCT01425723 Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
CBPO China Biologic Products, Inc. 2017-06-01 Phase 3 NCT02623556 Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen
CLVS Clovis Oncology, Inc. 2017-06-01 Phase 3 NCT02322281 TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
CRMD CorMedix Inc 2017-06-01 Phase 3 NCT02651428 Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection
EYEG Eyegate Pharmaceuticals, Inc. 2017-06-01 Phase 3 NCT02517619 Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
FGEN FibroGen, Inc 2017-06-01 Phase 3 NCT02278341 Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis
GRFS Grifols, S.A. 2017-06-01 Phase 3 NCT02413580 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
HZNP Horizon Pharma plc 2017-06-01 Phase 3 NCT01197378 Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
KTOV Kitov Pharmaceuticals Holdings Ltd. 2017-06-01 Phase 3 NCT02979197 Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives
MESO Mesoblast Limited 2017-06-01 Phase 3 NCT02336230 A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
MNK Mallinckrodt plc 2017-06-01 Phase 3 NCT02282930 Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression
NAVB Navidea Biopharmaceuticals, Inc. 2017-06-01 Phase 3 NCT01886820 A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology
NBIX Neurocrine Biosciences, Inc. 2017-06-01 Phase 3 NCT02736955 Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia
NOVN Novan, Inc. 2017-06-01 Phase 3 NCT02798120 P3 Long Term Safety Study of Once Daily SB204 in Acne
NVIV InVivo Therapeutics Holdings Corp. 2017-06-01 Phase 3 NCT02138110 The INSPIRE Study: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury
PRAH PRA Health Sciences, Inc. 2017-06-01 Phase 3 NCT02491437 A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)
PTCT PTC Therapeutics, Inc. 2017-06-01 Phase 3 NCT02090959 Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy
RARE Ultragenyx Pharmaceutical Inc. 2017-06-01 Phase 3 NCT02377921 Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
RDY Dr. Reddy's Laboratories Ltd 2017-06-01 Phase 3 NCT02569853 DFN-11 Injection in Episodic Migraine With or Without Aura
SAGE Sage Therapeutics, Inc. 2017-06-01 Phase 3 NCT02477618 A Study With SAGE-547 for Super-Refractory Status Epilepticus
ZGNX Zogenix, Inc. 2017-06-01 Phase 3 NCT02826863 A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
ZGNX Zogenix, Inc. 2017-06-01 Phase 3 NCT02823145 An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome